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Brk, a tyrosine kinase expressed in a majority of
breast tumors, but not normal mammary tissue, pro-
motes breast carcinoma cell proliferation. Normal ep-
ithelial cells are dependent on cell–cell or cell–matrix
interactions for survival and undergo apoptosis after
disruption of these interactions. Tumor cells are less
sensitive to the induction of apoptosis and are pre-
dicted to have the potential to disseminate. We inves-
tigated whether Brk has further roles in breast tumor
progression by relating its expression to tumor grade
and demonstrating its role in the regulation of carci-
noma cell survival under non-adherent conditions.
Brk expression was determined by reverse transcrip-
tion PCR on RNA extracted from surgical samples of
human breast cancers. Breast carcinoma cell survival
in suspension culture was examined when Brk protein
levels were suppressed by RNA interference. Addition-
ally, the effect of experimentally overexpressing Brk in
otherwise Brk-negative breast carcinoma cells was as-
sessed. Brk mRNA expression was notably higher in
grade 3 breast tumors, as compared with lower tumor
grades. In suspension culture, Brk suppression in-
creased the rate of cell death, as compared with con-
trols, and this cell death program exhibited character-
istics of autophagy but not of apoptosis. Conversely,
experimental expression of Brk in Brk-negative cells
increased cell survival whereas kinase-inactive Brk did
not. Therefore, Brk enhances breast carcinoma cell sur-
vival in suspension, suggesting a role for Brk in sup-
porting breast cancer cell dissemination. (Am J Pathol
2009, 175:1226–1234; DOI: 10.2353/ajpath.2009.080811)
Breast tumor kinase (Brk)/protein tyrosine kinase 6
(PTK6) is a protein tyrosine kinase expressed in a high
proportion of breast tumors, but not normal mammary
tissue,1–3 and we and others have suggested that it may
represent a novel therapeutic target.4 In support of this,
we have previously shown that immortalized human
mammary luminal epithelial cells, transfected to express
Brk at pathologically relevant levels, show an increased
sensitivity to the mitogenic effect of epidermal growth
factor.5 In contrast, RNA interference-mediated down-
regulation of Brk expression in T-47D breast carcinoma
cells results in decreased proliferation.6 A role for Brk in
promoting cell proliferation has also been found by other
investigators, albeit in nontumorigenic human embryonic
kidney cells (HEK 293) and rat astrocytes.7,8
In addition to proliferative deregulation, tumor cells are
thought to acquire a variety of other characteristics that
contribute to their survival and dissemination [eg,9], and
we are interested in determining whether pathological
Brk expression in breast carcinomas impacts on these
properties. Notably, from the point of view of therapeutic
target validation, we have sought to determine whether
Brk might support carcinoma cell survival, and thus
whether Brk-targeted therapies might be expected to kill
tumor cells selectively under specific conditions operat-
ing during dissemination and metastasis.
Normal epithelial cells are dependent on either cell–
cell or cell–matrix interactions for their survival, and can
be induced to undergo apoptosis by disrupting their
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interactions with neighboring cells and the substratum/
basement membrane.10 The process of apoptosis in-
duced by loss of these interactions is termed “anoikis.”11
It has been suggested that loss of an adhesive function in
transformed epithelial cells is a critical step in the promo-
tion of a malignant phenotype and that even certain non-
tumorigenic epithelial cells (Madin-Darby canine kidney)
can acquire invasive properties when cellular adhesion is
blocked.12
Reduced sensitivity to anoikis is an important step in
the tumor metastatic process and cells with increased
survival in the absence of attachment would be predicted
to have an increased potential to disseminate success-
fully (eg, via the vascular or lymphatic circulation). Hu-
man mammary luminal epithelial cells modified to ex-
press Brk show an increased efficiency of colony
formation and growth in soft agar, suggesting that Brk
may play a role in anchorage-independent survival
and/or proliferation in this cell type.5 We have therefore
tested the hypothesis that Brk is involved in preventing
the detachment-induced cell death of breast carcinoma
cells.
Materials and Methods
Preparation of Tissue Samples
Samples were collected with approval of the Norwich
District Ethics Committee, the Norwich Research and
Development Committee, and the Partners in Cancer
Research Tissue Bank Committee.
Human Breast Tumor Samples
Forty-six women ages 40 to 88 years (median age, 58
years) provided samples of 48 primary breast neoplasms
(all of which were invasive carcinoma) after providing
informed consent. Two patients who had bilateral disease
gave two samples, one from each side. All samples were
taken from fresh, unfixed carcinomas removed surgically.
The specimens were sent immediately after removal
to the laboratory, where, after inking the margins and
slicing the specimen, a small part of the tumor was re-
moved by a histopathologist for this study. Specimens
were prepared and snap-frozen in the department’s (Nor-
wich) human tissue bank as previously described.13 The
rest of the surgical specimen was fixed in 10% formal
saline and processed for routine histopathological diag-
nosis and establishment of prognostic factors.
Non-Neoplastic Human Mammary Tissue
Samples of non-neoplastic mammary tissue were ob-
tained from seven patients, with informed consent, at
reduction mammoplasty. All samples were snap-frozen
and stored as described for the cancers.
RNA Extraction
RNA was extracted from 44 of the frozen human breast
tumor surgical samples for which histological grade had
been determined, and the seven non-neoplastic human
mammary tissue samples. Total RNA was isolated using
a modification of the SV Total RNA Isolation System (Pro-
mega, Madison, WI14;). Fifty to 100 mg of tumor tissue
were homogenized in 1 ml of RNazol B reagent (Biogen-
esis Ltd., Poole, United Kingdom) using an UltraTurrax T8
homogenizer (IKA). The homogenate was stored at
80°C pending the following step of the protocol: the
samples were allowed to thaw completely at room tem-
perature, vortexed briefly, and collected into 200 l of
chloroform. They were shaken vigorously for 15 seconds,
incubated for 3 minutes at room temperature, and cen-
trifuged for 15 minutes at 14,000 rpm. The upper phase
was collected into 200 l of 95% ethanol, mixed, and
transferred into a spin basket assembly. The Promega
protocol was then followed from step 7 to the end ac-
cording to the manufacturer’s instructions.
Reverse Transcription (for Real-Time PCR)
One g of total RNA was primed with 0.5 g of random
hexameric primers (Promega) and reverse transcribed
into cDNA in a 20 l reaction volume containing 200 units
of SuperScript II reverse transcriptase, 5  first-strand
buffer (final concentrations: 50 mmol/L Tris-HCl [pH8.3],
75 mmol/L KCl, and 3 mmol/L MgCl2), 10 mmol/L dithio-
threitol, 0.5 mmol/L of each deoxynucleotide triphosphate
(dATP, dCTP, dGTP, and dTTP; Life Technologies, Inc.),
and 40 units of RNasin RNase inhibitor (Promega). Each
priming reaction was performed at 70°C for 10 minutes
and stopped by placing samples on ice; the reverse
transcription was performed at 42°C for 1 hour followed
by incubation at 70°C for 10 minutes.
TaqMan Real-Time PCR
Forward and reverse primers and fluorescence-labeled
oligonucleotide probes (using 6-carboxy-fluorescein
[FAM] as the reporter dye and 6-carboxytetramethylrho-
damine [TAMRA] as the quencher dye) were designed
for the human Brk/PTK6 gene using Primer Express 1.0
software (PE Applied Biosystems, Foster City, CA) and
synthesized by PE Applied Biosystems (Warrington,
United Kingdom). BLASTN searches were undertaken on
our designed primers to confirm gene specificity. To
ensure against genomic DNA amplification, the forward
and reverse primers were placed in separate adjacent
exons. Details of the primers are given in Table 1. A
standard curve with concentrations ranging from 25 ng to
1 ng was produced using human placental cDNA dis-
sected from fetal villi as the template. An XY scatter plot
for each gene was produced using Microsoft Excel Chart
Wizard software, and values for the equation y  mx  b
(where m  the slope of the standard curve and b  the
y intercept of that line) and R2 were obtained. The 18S
rRNA gene was used as an endogenous control to nor-
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malize for differences in the amount of total RNA in each
sample. PCR reactions for all samples were performed in
duplicate in 96-well optical plates with 5 ng of cDNA (1 ng
of cDNA for the 18S gene), 100 nmol/L probe, 200 nmol/L
each primer, and 12.5 l of TaqMan Universal 2  PCR
Master Mix (PE Applied Biosystems, Warrington, UK) in a
25 l reaction volume. The amplification reaction was
performed over 40 cycles with the following parameters:
an initial holding stage of 2 minutes at 50°C and then 10
minutes at 95°C, followed by a two-step cycling program
of 15 seconds at 95°C and 1 minute at 60°C.
Reverse Transcription
Seven hundred nanograms of total RNA was primed with
0.5 g of random hexameric primers (Promega) and
reverse transcribed into cDNA in a 20 l reaction volume
containing 200 units of SuperScript II reverse transcrip-
tase, 5  first-strand buffer (final concentrations: 50
mmol/L Tris-HCl [pH8.3], 75 mmol/L KCl, and 3 mmol/L
MgCl2), 10 mmol/L dithiothreitol, 0.5 mmol/L of each
deoxynucleotide triphosphate (dATP, dCTP, dGTP, and
dTTP; Life Technologies, Inc.), and 40 units of RNasin
RNase inhibitor (Promega). Each priming reaction was
performed at 70°C for 10 minutes and stopped by plac-
ing samples on ice; the reverse transcription was per-
formed at 42°C for 50 minutes followed by incubation at
70°C for 15 minutes.
PCR
PCR amplification was performed with the following pa-
rameters: denaturation at 94°C, followed by primer an-
nealing at 55°C and an extension step of 72°C for 35
cycles (Beclin-1) and 25 Cycles (-actin). Primer se-
quences are given in Table 1.
Cell Culture
T-47D and MDA-MB-157 breast carcinoma cells (ATCC
HTB-133 and HTB-24) were cultured in RPMI-1640 sup-
plemented with 10% fetal bovine serum, 2 mmol/L glu-
tamine, 100 U/ml penicillin, and 100 g/ml streptomycin
at 37°C in a humidified atmosphere of 5%CO2 in air.
GI101 cells were cultured under the same conditions but
with additional medium supplementation of 10 g/ml in-
sulin. Cells were subcultured twice weekly.
RNA Interference
Small interfering (si)RNAs with dTdT overhangs (Dharma-
con, Lafeyette, Co) (Table 1) were dissolved in annealing
buffer (20 mmol/L KCl, 6 mmol/L HEPES-KOH pH 7.5, 0.2
mmol/L MgCl2) to a final concentration of 20 mol/L.
T-47D cells were seeded at 1.25  106 cells per 25 cm2
tissue culture flask and allowed to adhere overnight. Be-
fore transfection the medium was exchanged (with wash-
ing) for 4.8 ml serum free medium. Transfections of siRNA
(sequences in Table 1) with 37.5 l Oligofectamine (In-
vitrogen) were performed according to manufacturer’s
instructions and as previously described6 to give a final
siRNA concentration per flask of 120 nmol/L. Four hours
after transfection fetal calf serum was added to a final
concentration of 10%. A second transfection was per-
formed 24 hours later. Duplicate independent Brk-target-
ing siRNAs were used in initial validation experiments
and the BrkA sequence was prioritized as it gave more
consistent reproducible suppression.
Stable Transfections
Duplicate stable Brk expressing MDA-MB-157 polyclonal
cell populations were generated by transfecting MDA-
MB-157 cells with pRcCMV encoding wild-type Brk (pRc-
CMV-WT-Brk) or pRcCMV alone (as a vector control).
Transfections were performed with a 3:1 ratio of Fugene
(Roche, West Sussex, United Kingdom):DNA following
the manufacturer’s protocol. Forty eight hours after trans-
fection, cells were subcultured into fresh medium con-
taining 400 g/ml G418 (Invitrogen, Paisley, United King-
dom). The medium was changed twice weekly and the
cells were maintained in 400 g/ml G418.
Cell Suspension Assay
Tissue culture plates were coated with a volume of
poly(2-hydroxyethylmethacrylate) (polyHEMA, Sigma,
Poole, United Kingdom) in 98% ethanol (20 mg/ml) to
give a final polyHEMA concentration of 1.5 mg/cm2.
Plates were air dried in a tissue culture cabinet. Cells
were seeded into polyHEMA-coated wells at 0.75  104
cells/cm2. Cell viability was assessed by incubating a
volume of cell suspension with an equal volume of 0.2%
trypan blue solution for 1 minute, followed by counting on
an improved Neubauer hemocytometer.
Table 1. PCR-Primer and siRNA Sequences
Name Sequence
Brk forward
primer
5-ATGAAGAAGCTGCGGCACAA-3
Brk reverse
primer
5-CCGAAACGGGCAGGACTT-3
Brk probe 5-FAM-ACATCATCACGGAGCTCATGGC-
CAAG-TAMRA-3
18S primers
and probe
Ribosomal RNA Control Reagent
(PE Applied Biosystems)
Actin forward
primer
5-AAGAGAGGCATCCTCACCCT-3
Actin reverse
primer
5-TACATGGCTGGGGTGTTGAA-3
Beclin forward
primer
5-GGCAAGATTGAAGACACAGG-3
Beclin reverse
primer
5-ATGGCATGTTGTAGCTCTGG-3
Control siRNA 5-GGACACCAUCAAGUGUUCG-3
Brk siRNA A 5-GGUGAUUUCUCGAGACAAC-3
Brk siRNA B 5-GCUUGUGAACUACCACAGG-3
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Annexin V Staining
The proportion of cells with exposed phosphatidyl serine
on the cell surface was measured using the Annexin
V-FITC fluorescein isothiocyanate (FITC) staining kit (BD
Clontech) according to the manufacturer’s protocol and
analyzing the stained cells by flow cytometry on a Beck-
man Coulter flow cytometer with Cell Quest software
(Becton Dickinson, Oxford, United Kingdom).
Cell Death Enzyme-Linked Immunosorbent
Assay
Levels of fragmented DNA were measured using the cell
death detection sandwich ELISAPLUS assay (Roche Ap-
plied Science), which uses anti-DNA and histone anti-
bodies to determine levels of mono- and oligonucleo-
somes in the cytoplasmic fraction of cell lysates, a marker
of apoptosis-induced DNA cleavage. After 24 hours on
polyHEMA 5  104 cells from duplicate wells were resus-
pended in 1 ml lysis buffer and the assay was performed
according to manufacturer’s instructions. A reagent only
background value was subtracted from the absorbance
values for experimental samples.
Immunoblotting
Cells for analysis were lysed in 2  SDS-polyacrylamide
gel electrophoresis lysis buffer and proteins separated
by SDS-polyacrylamide gel electrophoresis. After elec-
tro-transfer in Towbin buffer, membranes were blocked in
5% nonfat milk protein in TBS/0.1% Tween. Membranes
were then incubated at 4°C overnight with primary anti-
body in 5% nonfat milk protein/TBS/0.1% Tween; glycer-
aldehyde-3-phosphate dehydrogenase and Beclin-1
(Abcam, Cambridge, United Kingdom), or 5% bovine se-
rum albumin/TBS/0.1% Tween; Brk (ICR-100,5), caspase-3,
caspase-8, poly (ADP-Ribose) polymerase (PARP), and
Bcl-x (all Cell Signaling Technology, Hitchin, United King-
dom). Proteins were visualized with an appropriate horse-
radish peroxidase-conjugated secondary antibody (Dako,
Cambridge, United Kingdom) and chemiluminescent sub-
strate (Pierce, Warrington, United Kingdom).
Statistical Analysis
Statistical analysis was performed with Sigma STAT soft-
ware. Data were assessed for normality by the Kolmog-
orov-Smirnov test and significance determined by either
Mann Whitney U or Student’s t-test. P  0.05 was con-
sidered significant.
Results
To assess whether Brk expression is associated with
breast tumor grade, we analyzed Brk mRNA expression
levels using quantitative reverse-transcription PCR (Q-
RT-PCR) in 44 surgical samples of breast carcinoma of
known grade, and in seven non-neoplastic (normal)
mammary tissue samples obtained from reduction mam-
moplasty. We have previously shown by Western blotting
that over 60% of breast tumor samples express Brk,1 and
others have used Q-RT-PCR to corroborate this find-
ing.2,3 The data presented here suggest that approxi-
mately 85% of breast tumor samples tested were positive
for Brk mRNA expression. As Q-RT-PCR is a more sen-
sitive technique than Western blotting, this difference
might be predicted; however, it remains a possibility that
a subset of tumors express Brk mRNA but not protein.
Expression of mRNA confirms the previous Western blot-
ting data1 showing that Brk is frequently over expressed
in breast tumor samples compared with normal mam-
mary tissue (P  0.001). By plotting mRNA expression
levels against histopathological grade, a correlation be-
tween Brk expression and tumor grade was also noted
(Figure 1). Brk mRNA levels were significantly higher in
grade 3 breast tumors compared with those classed as
grades 1 and 2 (P  0.024).
Following from these findings on clinical samples, we
sought to determine whether Brk expression has an in-
fluence on breast carcinoma cell biology beyond its pro-
proliferative role. As histological grade reflects patterns
of metastatic spread and high grade tumors are associ-
ated with poor prognosis [eg,15], we hypothesized that
Brk may affect some of the processes involved in dis-
semination such as anchorage independent survival. To
determine whether Brk has a role in protecting breast
cancer cells from anoikis, T-47D cells were transfected
with siRNAs to suppress Brk expression (Figure 2A), and
plated into tissue culture wells that had either been
coated with polyHEMA to prevent attachment or left un-
treated. Initially we assessed the effects of Brk suppres-
sion on cell survival using the trypan blue exclusion as-
say, and the proportion of trypan blue permeable (and
therefore dead) cells was compared 24 hours after plat-
ing. When adhering to plastic, T-47D cells transfected
with Brk targeting siRNA showed only a small, statistically
insignificant increase in the proportion of trypan blue-
permeable cells compared with control transfectants. In
contrast, after 24 hours on polyHEMA, which completely
inhibited attachment, at least threefold more Brk-targeted
cells had incorporated trypan blue than cells transfected
with the control siRNA (Figure 2B). Additional transfec-
tions with a second Brk-targeting siRNA sequence6 gave
comparable results (data not shown). This suggests that
Brk targeting decreases the ability of T-47D breast car-
Figure 1. Brk expression increases with tumor grade. Relative levels of Brk
mRNA expression are plotted against histological grade. The horizontal bars
represent the mean normalized expression for each grade. Thirty-nine out of
44 samples were positive for Brk expression (determined by subtracting the
median of the normal breast samples from the tumor samples).
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cinoma cells to survive when detached from their normal
substratum.
If the expression of Brk protects T-47D cells from sus-
pension-induced cell death, we reasoned that transfect-
ing a Brk-negative breast carcinoma cell line with wild-
type Brk should reduce the levels of cell death in
suspension. We transfected the breast cancer cell line
MDA-MB-157 with plasmid alone or plasmid expressing
wild-type Brk (Brk WT) or kinase-inactive Brk (Brk K219M)
and selected stable polyclonal populations. After incuba-
tion on polyHEMA for 24 hours the levels of cell death
observed using the trypan blue exclusion assay de-
creased by almost half in the Brk WT transfected cells
compared with MDA-MB-157 cells transfected with vec-
tor only (Figure 3, A and B), showing that a gain in Brk
expression increases the survival of this breast cancer
cell line in suspension. Interestingly the levels of cell
death detected in cells transfected with kinase inactive
Brk were similar to those observed in the MDA-MB-157
cells transfected with vector only. Similar results were
also seen with MDA-MB-468 cells (data not shown).
We next wished to determine whether the Brk target-
ing-induced increase in the proportion of trypan blue
incorporating cells in suspension reflected death by ap-
optosis, using traditional markers such as cell-surface
exposure of phosphatidylserine, the appearance of cyto-
solic histone-bound DNA, activation of caspases 3 and 8,
and cleavage of PARP.
We assayed for loss of cell membrane polarity with
Annexin V-FITC using fluorescence-activated cell sorting
analysis to detect the cell surface exposure of phospha-
tidylserine molecules, one of the early markers of apopto-
sis [reviewed in16]. Only low levels of staining were de-
tected and no difference was observed between control
and Brk-targeted cells after 24 hours on polyHEMA (Fig-
ure 4A). We also observed very little difference in An-
nexin-v-FITC staining when T-47D cells were treated with
the broad spectrum kinase inhibitor staurosporine, as a
positive control for the induction of apoptosis, although
HeLa cells treated in parallel showed a shift in Annexin-
V-FITC fluorescence, confirming that the assay was func-
tioning (data not shown) and indicating that phosphati-
dylserine exposure is not a classical feature of cell death
in T-47D cells.
By assessing histone-bound DNA in the cytoplasm
resulting from cell death–associated DNA cleavage, we
observed no difference in DNA fragmentation between
control and Brk-targeted cells after 24 hours on poly-
HEMA (Figure 4A). Activation-associated cleavage of
caspases 3 and 8 were not detected in response to Brk
suppression in non-adherent T-47D cells; nor was cleav-
age of PARP, a caspase target in apoptotic cells (Figure
4B). T-47D cells treated with 1.5 mol/L staurosporine
were included in these experiments as a positive control
to confirm that DNA breaks, caspase activation, and
PARP cleavage could be detected in T-47D cells under-
going apoptosis (Figure 4, A and B).
Caspases are widely believed to be important execu-
tioners of apoptosis, and their activation is documented
in the induction of apoptosis by staurosporine in T-47D
cells.17 Untransformed epithelial cells undergoing de-
tachment-induced cell death show an increase in the
activation of both caspases 3 and 8.18 Although
caspase-8 is believed to be the effector caspase that
Figure 2. Brk suppression increases cell death in suspension culture. T-47D
cells were transfected twice with either control or Brk-targeting siRNAs and,
24 hours after the second transfection, cells were seeded into untreated or
polyHEMA-coated wells. A: Parallel wells of adherent cells were lysed in
SDS-polyacrylamide gel electrophoresis buffer 24 hours after the second
transfection, and Brk expression analyzed by immunoblotting (upper
panel), with glyceraldehyde-3-phosphate dehydrogenase as a loading con-
trol (lower panel). B: Cell viability of cells plated onto plastic or polyHEMA
was assessed by trypan blue exclusion. As the percentage of trypan-positive
cells varied with the efficacy of the knock-down, the proportion of trypan
blue-positive cells in Brk-targeted wells compared with controls for each
experiment was determined. The mean of three independent experiments is
plotted; *P  0.002.
Figure 3. Brk promotes survival of MDA-MD-157 cells in suspension. MDA-
MB-157 cells were transfected with pRcCMV vector alone (V), pRcCMV-Brk
WT) or pRcCMV-Brk K219M (KM). A: Expression of Brk was confirmed by
Western blotting with anti-Brk antibodies and Coomassie staining was per-
formed to ensure equal loading. B: Cells were seeded into polyHEMA-coated
wells, and cell viability was assessed by trypan blue exclusion. The ratio of
trypan blue permeable cells in the Brk expressing cells was expressed as a
percentage of the vector controls. The mean of four wells is plotted. *P 
0.029.
1230 Harvey et al
AJP September 2009, Vol. 175, No. 3
initiates the cellular events after detachment that result in
apoptosis, it is also activated at a later stage, possibly
through a positive feedback mechanism in some cell
types.19 To determine whether other caspases might be
involved, we repeated the siRNA transfections and
seeded cells into polyHEMA-coated wells, with the addi-
tion of the broad spectrum caspase inhibitor zVAD-FMK
in replicate wells transfected with Brk siRNA (Figure 4C).
There was no change in trypan blue inclusion observed in
the Brk-suppressed cells treated with zVAD-FMK, when
compared with the dimethyl sulfoxide carrier-treated and
Brk-suppressed cells (P  0.24). To confirm the efficacy
of the caspase inhibitor, adherent T-47D cells were also
treated with 1.5 mol/L staurosporine and zVAD-FMK,
and caspase-3 cleavage assessed by Western blotting.
Caspase-3 cleavage was detected in cells treated with
staurosporine; however, cleavage was notably reduced
on inclusion of the caspase inhibitor, confirming that 20
mol/L zVAD-FMK is sufficient to inhibit caspase activa-
tion-associated cleavage in this cell line (Figure 4D).
We now know that there are caspase-independent cell
death pathways, such as autophagy [reviewed in20], and
the promotion of cell death by some agents in cells,
including T-47D, has already been shown to be indepen-
dent of any known caspases.21,22 Western blots of ly-
sates from Brk-suppressed cells in suspension culture
showed a decrease in the levels of Bcl-xL relative to
control transfectants. An increase in Bcl-xS was also ob-
served (Figure 5A). As Bcl-xL has been shown to play a
role in regulating autophagy,23 the hypothesis that Brk-
Figure 4. Brk-regulated cell death is not ‘clas-
sical’ apoptosis. T-47D cells were transfected
with either control (Control) or Brk–targeting
(Brk KO) siRNAs and seeded into polyHEMA-
coated plates. Additional adherent T-47D cells
were treated with 1.5 mol/L staurosporine
(STS) as positive controls where necessary. After
24 hours cells were harvested and assayed for
markers of apoptosis by (A) cell death enzyme-
linked immunosorbent assay measuring cytoso-
lic histone-bound DNA; or (B) immunoblotting
for the presence of cleaved caspases 3 and 8, as
well as PARP cleavage. C: T-47D cells were
transfected with siRNAs and seeded into poly-
HEMA-coated plates in the presence of carrier
(dimethyl sulfoxide) or 20 mol/L zVAD-FMK.
The proportion of trypan blue incorporating
cells was assessed as a percentage. D: Adherent
T-47D cells were treated with carrier (dimethyl
sulfoxide), 1.5 mol/L staurosporine (STS), or
1.5 mol/L staurosporine plus 20 mol/L zVAD-
FMK (SZ) and lysed in SDS-polyacrylamide gel
electrophoresis sample buffer. Lysates were an-
alyzed by Western blotting for the presence of
cleaved caspase-3 to confirm efficacy of the
zVAD-FMK.
Figure 5. Brk-regulated cell death has hall-
marks of autophagy. T-47D cells were trans-
fected with either control (Control/C) or Brk–
targeting (Brk/B) siRNAs and seeded into
polyHEMA coated plates. After 24 hours cells
were harvested and assayed for (A) Bcl-x ex-
pression by Western blotting. B: Cells were
seeded with or without the autophagy inhibitor
3-methyladenine and % cell death determined
by trypan blue inclusion. *P  0.005. After 24
hours on polyHEMA, protein and RNA were
harvested and assayed by (C) Western blotting
and (D) reverse transcription-PCR for Beclin-1
expression.
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targeting and suspension culture induced autophagic,
not apoptotic, cell death was tested. Cells were trans-
fected with siRNA and analyzed for the presence of mem-
brane bound vesicles by electron microscopy and for
changes in levels of Beclin-1. Beclin-1 is a critical protein
in the induction of autophagy.24 It interacts with Vps34
and Vps15 in the Beclin-1 interactome to induce cell
death25,26 and is inhibited by binding to Bcl-2 and
Bcl-xL.
27–29 Cells that were transfected with either con-
trol or Brk-targeting siRNA were found to contain mem-
brane bound vesicles, characteristic of autophagic
cells, although little difference in absolute number was
seen at the time points measured (data not shown).
Inclusion of the autophagy inhibitor 3-methyladenine in
the suspension cultures resulted in a significant de-
crease in cell death in Brk-targeted cells compared
with treatment with Brk siRNA alone. The levels of cell
death were decreased to a comparable level to that
shown by the control transfectants (Figure 5B). Be-
clin-1 mRNA and protein were found to be increased in
Brk-suppressed suspension cultures compared with
controls (Figure 5, C and D).
Thus detachment-induced cell death due to Brk sup-
pression does not manifest many of the common molec-
ular features of apoptosis, but is more characteristic of
autophagy.
To confirm that the protection from autophagic cell
death was not cell line specific, GI101 cells were trans-
fected with Brk targeting or control siRNA, and cells were
subsequently suspended in polyHEMA-coated wells for
20 hours. The levels of cell death were significantly in-
creased in the Brk-suppressed cells (Figure 6A), but to a
slightly lesser extent than previously seen in T-47D cells,
possibly because the background level of cell death in
the control transfectants was higher. In addition, the in-
crease in cell death in GI101 cells was accompanied by
an increase in Beclin expression (Figure 6B).
Discussion
We have previously shown that Brk suppression results in
decreased cell proliferation in the breast carcinoma cell
line T-47D,6 although we have not previously established
a link between Brk expression and breast cancer pro-
gression. We show here that Brk expression levels are
significantly higher in grade 3 breast cancers, as com-
pared with those samples graded as either 1 or 2. This
study corroborates the findings of other groups,3,30
showing that Brk is expressed in a higher proportion of
tumors than previously reported and that there is a rela-
tionship between expression levels and breast cancer
grade,31 with Brk expression being elevated in tumors
whose grade is typically associated with poor prognosis
[eg,15]. Our results show a marked similarity to those
published as part of a larger study by Lange and col-
leagues,30 suggesting that, at least in the Western hemi-
sphere, Brk expression is not a prognostic indicator that
is confined to geographical location. Other investigators
have identified positive associations between Brk mRNA
levels in breast tumors and positive estrogen receptor/
postmenopausal status2 and HER2 expression.3 Positive
association of Brk expression with estrogen receptor ex-
pression may also explain why it has been reported pre-
viously that Brk expression is correlated with increased
disease-free survival, despite expression levels being
higher in tumors of higher grade. The positive association
of Brk with HER2 is further strengthened by the demon-
stration of co-amplification of Brk and HER2, as well as
co-expression, in breast cancers. Brk overexpression
promoted cell cycle progression induced by HER2
through activation of the MAPK pathway and the Cyclin
E/CDK2 complex in the non-transformed mammary cell
line MCF-10A.32 More recent studies have indicated that
the previously identified Brk substrate BKS/STAP-233
may be required for Brk’s modulation of downstream
signaling elements such as STAT3.34 Future studies will
reveal whether Brk’s role in promoting HER2-induced
proliferation also requires BKS/STAP-2.
As Brk expression levels correlate with tumor grade,
we hypothesized that Brk plays a role in disease progres-
sion in Brk positive tumors. We used RNA interference to
reduce Brk protein levels to assess its role in protecting
breast cancer cells from suspension-induced cell death
as anchorage independent survival is a key process in
metastasis.12,35 We found that Brk-targeted cells showed
an increase in the percentage of dead cells when sus-
pended on polyHEMA for 24 hours, relative to control
transfectants, but did not exhibit the recognized hall-
marks of apoptosis. The cells rather demonstrated some
of the features of autophagy, suggesting that decreased
Brk expression in conjunction with suspension culture
can initiate autophagic cell death in breast carcinoma
cells. Conversely, experimental Brk expression protected
breast tumor cells from suspension-induced death and
this protection appeared to be dependent on the kinase
activity of Brk. These data support the hypothesis that Brk
plays a role in protecting breast cancer cells from de-
tachment-induced cell death. Therefore Brk expression in
carcinomas may confer a survival advantage on metas-
Figure 6. Autophagic phenotype is not cell line-specific. GI101 cells were
transfected with either control (Control/Cont) or Brk–targeting (Brk) siRNAs
and seeded into polyHEMA-coated plates. After 20 hours, cells were har-
vested and (A) % cell death determined by trypan blue inclusion; *P  0.007.
B: Beclin-1 levels were determined by Western blotting.
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tasizing tumor cells. This is in contrast to the data pre-
sented recently, where nontransformed rat fibroblasts
transfected with Brk were sensitized to inducers of apo-
ptosis rather than gaining a survival advantage, suggest-
ing that Brk may not be oncogenic in such cells.36 In-
deed, Brk’s ability to inhibit Akt activity (in COS1 cells)
might underlie such a pro-apoptotic role for Brk.37 How-
ever, in support of Brk having pro-tumorigenic activity,
parallels can be drawn with data on c-myc, as myc has
long been known to have oncogenic properties but is also
capable of sensitizing fibroblasts to induction of apoptosis
by serum deprivation [38 and refs therein,39,40]. Constitu-
tively active Brk has been shown to increase proliferation,
anchorage-independent colony formation and cell sur-
vival in HEK293 cells,7 further underlining the fact that
that the functions of Brk are likely to be dependent on
cellular context.31
So far, physiological Brk expression has not been de-
tected in nonepithelial cells, its normal expression pattern
being restricted to differentiating or differentiated epithe-
lial cells in the skin, gut, prostate, and oral mucosa.41–44
Our data identify a role for Brk in protecting cells from a
form of cell death that is not classically apoptotic but has
features of autophagy. Altering the ratio of Bcl-xL:Bcl-xS
by targeting Brk could reduce the Bcl-xL-mediated inhi-
bition of Beclin-1. Binding of Beclin to Bcl-xL or Bcl-2
27–29
inhibits Beclin, as it is then not available to bind to Vps34
and Vps15 in the Beclin interactome.25,26 Dissociation of
Beclin-1 from Bcl- xL is required for the induction of
autophagy and this process can be mediated by phos-
phorylation of Beclin on Thr119.45,46 In this study, Bcl-xL
levels were reduced on Brk targeting, suggesting that
there could be reduced inhibition of Beclin. We also
demonstrated that Brk suppression resulted in increased
Beclin expression, which contributed to the increased
cell death observed. Recently epidermal growth factor
has been shown to protect bovine mammary cells from
autophagic cell death47 providing further evidence that
Brk’s role in augmenting the effects of epidermal growth
factor signaling in mammary cells5,32 may not be limited
solely to proliferation and may include protection from
cell death. In addition, given that allelic loss of Beclin-1 is
common in breast cancers,24,48,49 our expression data
suggest that abrogation of Brk function may provide a
mechanism for restoring the autophagy pathway in cells
with decreased Beclin-1 levels. It remains to be seen
however whether this function is manifest in other Brk-
positive tumor cells from tissues other than the breast,
such as the colon and prostate.
Together with previous studies showing that experi-
mental Brk expression increases colony formation by
nontransformed breast epithelial cells on detachment5
and more recent data proposing a role for Brk in inva-
sion,50 our data show a potential role for Brk in one of the
processes that control metastasis of breast cancer cells:
promoting anchorage-independent survival. When con-
sidered alongside the fact that Brk expression is highest
in grade 3 tumors, targeting Brk, possibly by kinase
inhibition may provide the basis for antimetastatic
therapy.
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